4
64000-00137 Rev 1
3. GAMMACORE SAPPHIRE CV TREATMENT RECOMMENDATIONS
97
98
•
The gammaCore Sapphire CV is intended for acute use at home or in healthcare settings to
99
treat adult patients with known or suspected COVID-19 who are experiencing exacerbation
100
of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are
101
not tolerated or provide insufficient symptom relief as assessed by their healthcare
102
provider, using non-invasive vagus nerve stimulation (n
VNS) on either side of the patient’s
103
neck during the Coronavirus Disease 2019 (COVID-19) pandemic.
104
105
•
One treatment consisting of
two
consecutive 2-minute stimulations.
106
•
If the therapy does not provide relief, seek medical attention by consulting your Healthcare
107
Provider.
108
•
The use of more than 24 stimulations per day has not been evaluated in controlled clinical trials.
109
Do not use more than 24 stimulations in a 24-hour period.
110
111
112
113
114
115
116
117
118
119
120
121
For a detailed treatment guide, please refer to Section 12.9
122
123
124
125
Note: The remainder of this page was intentionally left blank.
126
127
128